Subodh Verma




Please note: Dr. Verma will not take students in summer.

Dr. Subodh Verma is an internationally renowned cardiac surgeon-scientist and Professor at the University of Toronto. He is the current Canada Research Chair in Cardiovascular Surgery, having previously served as the Canada Research Chair in Atherosclerosis (2007-2017). Dr. Verma was recently awarded the 2021 Lister Prize in Surgery from the University of Toronto in recognition of his outstanding and continuing productivity of international stature. He is a past recipient of the Howard Morgan Award for Distinguished Achievements in Cardiovascular Research and the Royal College of Physicians and Surgeons of Canada Gold Medal in Surgery. He is an appointee of the American Association of Thoracic Surgeons (AATS) and a member of the College of New Scholars, Artists and Scientists, Royal Society of Canada. According to Google Scholar in April 2021, Dr. Verma has an h-index of 100 and his work has been cited over 50,000 times.

Dr. Verma has published extensively in highly impactful journals like the NEJM, Lancet, Circulation, JACC, Nature, and JCI. He is an Associate Editor of the European Heart Journal. Dr. Verma is an active contributor to Canadian clinical practice guidelines and co-authored the recently updated recommendations for atrial fibrillation, antiplatelet therapy, diabetes, and heart failure; he was a member of the 2018 AATS consensus guidelines committee on bicuspid aortic valve-related aortopathy. Dr. Verma has served in various capacities on the American Heart Association Council on Cardiovascular Surgery and Anesthesia since 2008.

Dr. Verma had/has leadership roles on 10 contemporary global heart failure trials – several of which have let to paradigm changes in how individuals all around the world who live with diabetes and heart failure are now managed. He founded and oversees the CardioLink platform at St Michael’s Hospital that is conducting cardiometabolic and surgically oriented RCTs and translational studies.

Dr. Verma leads a dynamic pre-clinical and translational research team that leverages pre-clinical disease models and clinical trial-derived data to identify novel mediators of cardiovascular and cardiometabolic disease as well as answer timely and relevant healthcare questions. His research has yielded 2 United States patents and is supported by several national peer-reviewed grants.


Recent Publications

  1. McMurray, JJV, Docherty, KF, de Boer, RA, Hammarstedt, A, Kitzman, DW, Kosiborod, MN et al.. Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure: The DETERMINE Randomized Clinical Trials. Circulation. 2023; :. doi: 10.1161/CIRCULATIONAHA.123.065061. PubMed PMID:38059368 .
  2. Butler, J, Abildstrøm, SZ, Borlaug, BA, Davies, MJ, Kitzman, DW, Petrie, MC et al.. Semaglutide in Patients With Obesity and Heart Failure Across Mildly Reduced or Preserved Ejection Fraction. J Am Coll Cardiol. 2023;82 (22):2087-2096. doi: 10.1016/j.jacc.2023.09.811. PubMed PMID:37993201 .
  3. Usman, MS, Davies, M, Hall, ME, Verma, S, Anker, SD, Rosenstock, J et al.. The cardiovascular effects of novel weight loss therapies. Eur Heart J. 2023; :. doi: 10.1093/eurheartj/ehad664. PubMed PMID:37966486 .
  4. Barbour, W, Wolff, E, Puar, P, Hibino, M, Bakbak, E, Krishnaraj, A et al.. Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial. BMC Cardiovasc Disord. 2023;23 (1):557. doi: 10.1186/s12872-023-03549-5. PubMed PMID:37964221 PubMed Central PMC10648366.
  5. Kosiborod, MN, Verma, S, Borlaug, BA, Butler, J, Davies, MJ, Jensen, TJ et al.. Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial. Circulation. 2023; :. doi: 10.1161/CIRCULATIONAHA.123.067505. PubMed PMID:37952180 .
  6. Mc Causland, FR, Claggett, BL, Vaduganathan, M, Desai, A, Jhund, P, Vardeny, O et al.. Decline in Estimated Glomerular Filtration Rate After Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial. JAMA Cardiol. 2023; :. doi: 10.1001/jamacardio.2023.4664. PubMed PMID:37952176 PubMed Central PMC10641768.
  7. Patel, KV, Segar, MW, Klonoff, DC, Khan, MS, Usman, MS, Lam, CSP et al.. Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: a Pooled Cohort Analysis. Circulation. 2023; :. doi: 10.1161/CIRCULATIONAHA.123.067530. PubMed PMID:37950893 .
  8. Verma, S, Mudaliar, S, Greasley, PJ. Potential Underlying Mechanisms Explaining the Cardiorenal Benefits of Sodium-Glucose Cotransporter 2 Inhibitors. Adv Ther. 2023; :. doi: 10.1007/s12325-023-02652-5. PubMed PMID:37943443 .
  9. Sharma, A, Marques, P, Neuen, BL, Fletcher, RA, Slee, A, Rapattoni, W et al.. Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. 2023; :. doi: 10.1111/dom.15340. PubMed PMID:37881140 .
  10. Goldenberg, RM, Teoh, H, Verma, S. Glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide receptor co-agonists for cardioprotection, type 2 diabetes and obesity: a review of mechanisms and clinical data. Curr Opin Cardiol. 2023;38 (6):539-545. doi: 10.1097/HCO.0000000000001084. PubMed PMID:37792556 .
Search PubMed

Affiliations & Other Activities

  • Cardiac Surgeon, Division of Cardiology , St. Michael’s Hospital
  • Professor of Surgery and Pharmacology & Toxicology, University of Toronto
  • Canada Research Chair in Cardiovascular Surgery